Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 12/20 | 0.57 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.53 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.53 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.53 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 2/20 | 0.51 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5090791 | 0.90 | KCNQ2 (0.59) | MAOBKCNQ2KCNQ3KCNQ4KCNQ5 | |
| SCHEMBL5089259 | 0.90 | MAOB (0.52) | MAOBKCNQ2KCNQ3KCNQ4KCNQ5 | |
| SCHEMBL5090811 | 0.88 | KCNQ2 (0.65) | MAOBKCNQ2KCNQ3KCNQ4KCNQ5 | |
| SCHEMBL5090320 | 0.88 | ALDH1A1 (0.53) | MAOBKCNQ2KCNQ3KCNQ4KCNQ5 | |
| SCHEMBL5089346 | 0.87 | MAOB (0.55) | MAOBMAOANR4A2 | |
| SCHEMBL5090952 | 0.87 | NPC1 (0.56) | MAOBKCNQ2KCNQ3KCNQ4KCNQ5 | |
| SCHEMBL5090792 | 0.87 | KCNQ2 (0.55) | MAOBKCNQ2KCNQ3KCNQ4KCNQ5 | |
| SCHEMBL5087179 | 0.86 | MAOB (0.54) | MAOBKCNQ2KCNQ3NR4A2MRGPRX4 | |
| SCHEMBL5095875 | 0.84 | FFAR1 (0.51) | MAOBKCNQ2KCNQ3KCNQ4KCNQ5 | |
| SCHEMBL5090790 | 0.83 | KCNQ2 (0.49) | MAOBKCNQ2KCNQ3KCNQ4KCNQ5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080188561-A1 | N-[2-AMINO-4-(PHENYLMETHOXY)PHENYL] AMIDES AND RELATED COMPOUNDS AS POTASSIUM CHANNEL MODULATORS | JPMORGAN CHASE BANK, N.A. | 2008-08-07 | — | — | US | claimed |
| US-8722929-B2 | N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2014-05-13 | — | — | US | disclosed |
| US-20080188561-A1 | N-[2-AMINO-4-(PHENYLMETHOXY)PHENYL] AMIDES AND RELATED COMPOUNDS AS POTASSIUM CHANNEL MODULATORS | JPMORGAN CHASE BANK, N.A. | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188561-A1 | N-[2-AMINO-4-(PHENYLMETHOXY)PHENYL] AMIDES AND RELATED COMPOUNDS AS POTASSIUM CHANNEL MODULATORS | KCNB2, KCNJ2, KCNA2 | MAOB 808/4885KCNQ2 9/4885KCNQ3 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.